Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.57 |
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22938991 | 0.88 | MEN1 (0.58) | MAOAMAOBALDH1A1CA12CA1 | |
| SCHEMBL22939649 | 0.86 | ALDH1A1 (0.64) | MAOAMAOBALDH1A1TSHRMAPT | |
| SCHEMBL6205557 | 0.85 | KMT2A (0.72) | MAOAMAOBALDH1A1TSHRMAPT | |
| SCHEMBL29570529 | 0.85 | KMT2A (0.72) | MAOAMAOBALDH1A1TSHRMAPT | |
| SCHEMBL144363 | 0.84 | MAOB (0.57) | MAOAMAOBALDH1A1TSHRMAPT | |
| SCHEMBL130505 | 0.84 | CSNK2A1 (0.57) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL30728533 | 0.84 | MAOB (0.57) | MAOAMAOBALDH1A1TSHRMAPT | |
| SCHEMBL22939013 | 0.84 | ALDH1A1 (0.61) | MAOAMAOBALDH1A1CA12CA1 | |
| SCHEMBL8646935 | 0.83 | SLC16A3 (0.51) | MAOAMAOBALDH1A1TSHRMAPT | |
| SCHEMBL22939007 | 0.83 | MEN1 (0.60) | MAOAMAOBALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528921-A | Rhodamine-coumarin based fluorescent probe, fluorescent sensitive film, and preparation methods and applications thereof | 兰州大学 | 2025-02-28 | — | — | CN | claimed |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | claimed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| EP-2844242-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | Nogra Pharma Limited (IE) | 2015-03-11 | — | — | EP | claimed |
| CN-104284655-A | Methods of treating lactose intolerance | NOGRA PHARMA LTD | 2015-01-14 | — | — | CN | claimed |
| WO-2013156413-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | claimed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | claimed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | claimed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | claimed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | claimed |
| US-12291494-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2025-05-06 | — | — | US | disclosed |
| CN-119528921-A | Rhodamine-coumarin based fluorescent probe, fluorescent sensitive film, and preparation methods and applications thereof | 兰州大学 | 2025-02-28 | — | — | CN | disclosed |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2024-08-22 | — | — | US | disclosed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| CN-116602950-A | Methods of treating fibrosis | 诺格拉制药有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-5055374-A | Positive working resist | NIPPON PAINT CO., LTD. (JP) | 1991-10-08 | — | — | US | disclosed |
| US-4999274-A | Obtained by Reacting a Polyepoxide Compound, an Aromatic or Heterocyclic Carboxylic Acid Bearing a Phenolic Hydroxyl Group and a 1,2-Quinondiazido Sulfonyl Halide; Lithographic Plates, Photoresists | NIPPON PAINT CO., LTD. (JP) | 1991-03-12 | — | — | US | disclosed |
| EP-0354018-A2 | An electrodeposition coating composition and image-forming method using the same | NIPPON PAINT CO., LTD. (JP) | 1990-02-07 | — | — | EP | disclosed |
| EP-0302941-A1 | POSITIVE PHOTOSENSITIVE RESIN COMPOSITION AND PROCESS FOR ITS PRODUCTION | NIPPON PAINT CO., LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
| US-4247597-A | Electroscopic carrier particles having a carboxylic acid surface treatment | PITNEY BOWES, INC. (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | MAOA 3924/4885MAOB 3247/4885ALDH1A1 2287/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | MAOA 1738/4885MAOB 950/4885ALDH1A1 664/4885 |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | MAOA 1738/4885MAOB 950/4885ALDH1A1 664/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | MAOA 3500/4885MAOB 2825/4885ALDH1A1 530/4885 |
| US-12291494-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | MAOA 1738/4885MAOB 950/4885ALDH1A1 664/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | MAOA 3500/4885MAOB 2825/4885ALDH1A1 530/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | MAOA 3577/4885MAOB 3944/4885ALDH1A1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.